Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up – Should You Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares gapped up before the market opened on Monday . The stock had previously closed at $10.0250, but opened at $10.48. Santen Pharmaceutical shares last traded at $10.78, with a volume of 2,504 shares trading hands.

Analyst Ratings Changes

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 5.5%

The company’s 50 day simple moving average is $10.96 and its 200-day simple moving average is $10.67. The firm has a market cap of $3.40 billion and a P/E ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.